Globus Medical (GMED) EBITDA (2011 - 2026)

Globus Medical (GMED) has reported EBITDA for 16 consecutive years, with $182.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 139.7% year-over-year to $182.4 million; the trailing twelve-month figure through Jun 2026 stood at $639.5 million (up 127.2% YoY), and the FY2025 full-year result was $479.8 million, up 189.06% from the prior year.
• EBITDA rose to $182.4 million in Q2 2026 per GMED's latest filing, from $150.4 million in the prior quarter.
• Across five years, EBITDA topped out at $182.4 million in Q2 2026 and bottomed at $404000.0 in Q3 2023.
• Historically, EBITDA has averaged $74.4 million across 5 years, with a median of $60.0 million in 2022.
• The sharpest annual moves came in 2023 and 2024: EBITDA slumped 99.32% in 2023, then jumped 11805.45% in 2024.
• Over 5 years, EBITDA stood at $54.0 million in 2022, then slumped by 81.26% to $10.1 million in 2023, then soared by 495.42% to $60.3 million in 2024, then soared by 180.95% to $169.3 million in 2025, then advanced by 7.73% to $182.4 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $182.4 million, $150.4 million, and $169.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.